サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1452675

悪性中皮腫の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤タイプ別、投与経路別、流通チャネル別、地域別

Malignant Mesothelioma Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日: | 発行: Fairfield Market Research | ページ情報: 英文 223 Pages | 納期: 2～5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
悪性中皮腫の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤タイプ別、投与経路別、流通チャネル別、地域別
出版日: 2024年03月06日
発行: Fairfield Market Research
ページ情報: 英文 223 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

世界の悪性中皮腫の市場規模はパラダイムシフトを迎えており、ペメトレキセドと併用療法分野が治療アプローチに革命を起こすフロントランナーとして台頭しています。このセグメントは予測期間終了までに45％以上の収益シェアを占め、市場の大部分を占めると予測されています。年間平均成長率（CAGR）は7.4％と目覚ましく、優れた奏効率と併用療法への注目の高まりにより、同分野は3億米ドルを超える勢いです。

ペメトレキセドは、単独療法でも他剤との併用療法でも顕著な有効性を示すことから、悪性中皮腫治療の要としての地位が確立しています。臨床試験の結果、ペメトレキセドを併用した場合の奏効率は30％から40％であることが明らかになり、市場シェアの大幅な拡大への道が開かれました。各社は、異なる薬剤の相乗効果を利用して患者の転帰を向上させる新しい併用療法レジメンの承認取得に向けた取り組みを強化しています。

悪性中皮腫治療における併用療法の可能性を探るため、業界各社の間で共同研究が重要な戦略として浮上しています。手技に関する特許を保有する企業の数が限られているため、多様な薬剤の組み合わせに焦点を当てた共同研究のイニシアチブが支持を集めています。特に、ベーリンガーインゲルハイムによるニンテダニブとペメトレキセド/シスプラチンの併用療法の第3相試験は、治療の選択肢を増やし、治療の展望を広げるための協調的な取り組みを例証するものです。

当レポートでは、世界の悪性中皮腫市場について調査し、市場の概要とともに、薬剤タイプ別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の悪性中皮腫市場の見通し、2018年～2031年

  • 世界の悪性中皮腫市場の見通し、薬剤タイプ別、金額（10億米ドル）、2018年～2031年
  • 世界の悪性中皮腫市場の見通し、投与経路別、金額（10億米ドル）、2018年～2031年
  • 世界の悪性中皮腫市場の見通し、流通チャネル別、金額（10億米ドル）、2018年～2031年
  • 世界の悪性中皮腫市場の見通し、地域別、金額（10億米ドル）、2018年～2031年

第4章 北米の悪性中皮腫市場の見通し、2018年～2031年

第5章 欧州の悪性中皮腫市場の見通し、2018年～2031年

第6章 アジア太平洋の悪性中皮腫市場の見通し、2018年～2031年

第7章 ラテンアメリカの悪性中皮腫市場の見通し、2018年～2031年

第8章 中東・アフリカの悪性中皮腫市場の見通し、2018年～2031年

第9章 競合情勢

  • 薬剤タイプ別と投与経路別のヒートマップ
  • 企業の市場シェア分析、2023年
  • 競争力ダッシュボード
  • 企業プロファイル
    • AstraZeneca Plc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Eli Lilly and Company
    • Teva Pharmaceuticals
    • Boehringer Ingelheim GmbH
    • Mylan N.V.
    • Fresenius Kabi AG
    • Sun Pharmaceuticals Industries Ltd
    • Corden Pharma International GmbH
    • Concordia International Corp

第10章 付録

目次

The global malignant mesothelioma market is witnessing a paradigm shift, with the Pemetrexed and combination therapy segment emerging as the frontrunner in revolutionizing treatment approaches. According to comprehensive market analysis, this segment is anticipated to capture a significant portion of the market, accounting for over 45% revenue share by the end of the forecast period. With an impressive compound annual growth rate (CAGR) of 7.4%, the segment is poised to exceed US$ 300 million, driven by its superior response rates and increasing focus on combination therapies.

Enhanced Efficacy Fuels Growth

The remarkable efficacy demonstrated by Pemetrexed, either as a standalone therapy or in combination with other drugs, underscores its position as the cornerstone of malignant mesothelioma treatment. Clinical studies have revealed response rates ranging from 30% to 40% when Pemetrexed is used in combination, paving the way for a significant expansion in market share. Companies are intensifying efforts to secure approvals for novel combination therapy regimens, leveraging the synergistic effects of different drugs to enhance patient outcomes.

Collaborative Research Drives Innovation

Collaboration has emerged as a key strategy among industry players to explore the potential of combination therapies in malignant mesothelioma treatment. With a limited number of companies holding patents for procedures, collaborative research initiatives have gained traction, focusing on diverse combinations of drugs. Notably, Boehringer Ingelheim's phase 3 study of Nintedanib in combination with Pemetrexed/Cisplatin exemplifies the concerted efforts towards advancing treatment options and expanding the therapeutic landscape.

Rising Incidence Promotes Market Growth

Contrary to assumptions based on asbestos restrictions, the incidence of malignant mesothelioma continues to rise, particularly among men. Statistics released by Cancer Research UK highlight a concerning trend, with 1 in every 140 men and 1 in every 710 women diagnosed with the disease. This demographic shift underscores the urgent need for effective therapeutic interventions, propelling the demand for Pemetrexed and combination therapies.

Exploring Combination Therapies

The evolution of combination therapies represents a pivotal advancement in the management of malignant mesothelioma, offering a multifaceted approach to tumor regulation. By targeting multiple pathways involved in tumor progression, combination therapies hold promise in significantly improving survival rates. Various modalities, including chemotherapy combined with radiotherapy, targeted antibodies, cryotherapy, and immunotherapies, are poised to expand the potential indications for existing drugs, providing hope for patients and clinicians alike.

Regional Dynamics

While the global market for malignant mesothelioma is poised for substantial growth, regional variations in market dynamics are evident. The Asia Pacific, Latin America, and Middle East & Africa regions are projected to witness the highest CAGRs for the Pemetrexed and combination therapy segment. With a market attractiveness index of 2.7, Latin America emerges as a particularly promising market, reflecting the growing acceptance and adoption of innovative treatment modalities.

Key Companies

  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Eli Lilly and Company
  • Teva Pharmaceuticals
  • Boehringer Ingelheim GmbH
  • Mylan N.V.
  • Fresenius Kabi AG
  • Sun Pharmaceuticals Industries Ltd
  • Corden Pharma International GmbH
  • Concordia International Corp
  • Kyowa Hakko Kirin Co Ltd.
  • Polaris Pharmaceuticals, Inc.
  • MolMed SpA
  • Ono Pharmaceutical Co. Ltd
  • Nichi-Iko Pharmaceutical Co., Ltd
  • Others.

Market Segmentation:

Drug Type

  • Pemetrexed
  • Cisplatin
  • Carboplatin
  • Gemcitabine
  • Vinorelbine
  • Others

Route of Administration

  • Oral
  • Parenteral

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Oncology Centers

Region

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

Table of Contents

1. Executive Summary

  • 1.1. Global Malignant Mesothelioma Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 3.1. Global Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Pemetrexed
      • 3.1.1.2. Cisplatin
      • 3.1.1.3. Carboplatin
      • 3.1.1.4. Gemcitabine
      • 3.1.1.5. Vinorelbine
      • 3.1.1.6. Others
  • 3.2. Global Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Oral
      • 3.2.1.2. Parenteral
  • 3.3. Global Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospital Pharmacies
      • 3.3.1.2. Retail Pharmacies
      • 3.3.1.3. Oncology Centres
  • 3.4. Global Malignant Mesothelioma Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 4.1. North America Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Pemetrexed
      • 4.1.1.2. Cisplatin
      • 4.1.1.3. Carboplatin
      • 4.1.1.4. Gemcitabine
      • 4.1.1.5. Vinorelbine
      • 4.1.1.6. Others
  • 4.2. North America Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oral
      • 4.2.1.2. Parenteral
  • 4.3. North America Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospital Pharmacies
      • 4.3.1.2. Retail Pharmacies
      • 4.3.1.3. Oncology Centres
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Malignant Mesothelioma Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 5.1. Europe Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Pemetrexed
      • 5.1.1.2. Cisplatin
      • 5.1.1.3. Carboplatin
      • 5.1.1.4. Gemcitabine
      • 5.1.1.5. Vinorelbine
      • 5.1.1.6. Others
  • 5.2. Europe Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oral
      • 5.2.1.2. Parenteral
  • 5.3. Europe Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospital Pharmacies
      • 5.3.1.2. Retail Pharmacies
      • 5.3.1.3. Oncology Centres
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Malignant Mesothelioma Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Malignant Mesothelioma Market by Route of Administration,Value (US$Bn), 2018 - 2031
      • 5.4.1.12. Italy Malignant Mesothelioma Market by Distribution Channel, Value(US$Bn), 2018 - 2031
      • 5.4.1.13. Turkey Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Pemetrexed
      • 6.1.1.2. Cisplatin
      • 6.1.1.3. Carboplatin
      • 6.1.1.4. Gemcitabine
      • 6.1.1.5. Vinorelbine
      • 6.1.1.6. Others
  • 6.2. Asia Pacific Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oral
      • 6.2.1.2. Parenteral
  • 6.3. Asia Pacific Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospital Pharmacies
      • 6.3.1.2. Retail Pharmacies
      • 6.3.1.3. Oncology Centres
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Malignant Mesothelioma Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Malignant Mesothelioma Market by Route of Administration,Value (US$Bn), 2018 - 2031
      • 6.4.1.12. India Malignant Mesothelioma Market by Distribution Channel, Value(US$Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 7.1. Latin America Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Pemetrexed
      • 7.1.1.2. Cisplatin
      • 7.1.1.3. Carboplatin
      • 7.1.1.4. Gemcitabine
      • 7.1.1.5. Vinorelbine
      • 7.1.1.6. Others
  • 7.2. Latin America Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Oral
      • 7.2.1.2. Parenteral
  • 7.3. Latin America Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospital Pharmacies
      • 7.3.1.2. Retail Pharmacies
      • 7.3.1.3. Oncology Centres
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Malignant Mesothelioma Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Pemetrexed
      • 8.1.1.2. Cisplatin
      • 8.1.1.3. Carboplatin
      • 8.1.1.4. Gemcitabine
      • 8.1.1.5. Vinorelbine
      • 8.1.1.6. Others
  • 8.2. Middle East & Africa Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Oral
      • 8.2.1.2. Parenteral
  • 8.3. Middle East & Africa Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospital Pharmacies
      • 8.3.1.2. Retail Pharmacies
      • 8.3.1.3. Oncology Centres
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Malignant Mesothelioma Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Malignant Mesothelioma Market by Distribution Channel,Value (US$Bn), 2018 - 2031
      • 8.4.1.7. Egypt Malignant Mesothelioma Market by Drug Type, Value (US$Bn), 2018 - 2031
      • 8.4.1.8. Egypt Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Drug Type vs by Route of Administration Heat map
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. AstraZeneca Plc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Bristol-Myers Squibb Company
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. F. Hoffmann-La Roche Ltd.
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Merck & Co., Inc.
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Novartis AG
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Pfizer Inc.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Sanofi
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Eli Lilly and Company
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Teva Pharmaceuticals
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Boehringer Ingelheim GmbH
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. Mylan N.V.
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Product Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development
    • 9.4.12. Fresenius Kabi AG
      • 9.4.12.1. Company Overview
      • 9.4.12.2. Product Portfolio
      • 9.4.12.3. Financial Overview
      • 9.4.12.4. Business Strategies and Development
    • 9.4.13. Sun Pharmaceuticals Industries Ltd
      • 9.4.13.1. Company Overview
      • 9.4.13.2. Product Portfolio
      • 9.4.13.3. Financial Overview
      • 9.4.13.4. Business Strategies and Development
    • 9.4.14. Corden Pharma International GmbH
      • 9.4.14.1. Company Overview
      • 9.4.14.2. Product Portfolio
      • 9.4.14.3. Financial Overview
      • 9.4.14.4. Business Strategies and Development
    • 9.4.15. Concordia International Corp
      • 9.4.15.1. Company Overview
      • 9.4.15.2. Product Portfolio
      • 9.4.15.3. Financial Overview
      • 9.4.15.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations

List of Region/Countries

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Turkey
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa